Match Document Document Title
US20180327460 MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO  
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use...
10124051 Meningococcus serogroup X conjugate  
The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidizing a primary hydroxyl group...
10124050 Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof  
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic...
US20180318410 COMBINATION VACCINES WITH SEROGROUP B MENINGOCOCCUS AND D/T/P  
Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple...
US20180318407 PCSK9 VACCINE  
The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of...
10117933 Antibodies against Clostridium difficile  
Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The...
10117920 Combination of vaccination and inhibition of the PD-1 pathway  
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one...
US20180312545 OPTIMIZED NUCLEIC ACID MOLECULES  
The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is...
10113009 Methods for making saccharide-protein glycoconjugates  
The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and...
US20180299444 SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION  
To overcome the limitations of existing particle quantification techniques, the inventors used disc centrifugation in combination with a detector, to quantify particles, in particular virus...
US20180298064 PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI  
Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing...
US20180296663 VACCINE COMPOSITION  
A composition or combination comprising at least a first immunogenic component and at least a second adjuvant component, wherein the first immunogenic component comprises at least one nucleic acid...
US20180282377 HEPATITIS C VIRUS E1/E2 HETERODIMERS AND METHODS OF PRODUCING SAME  
The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2...
US20180280507 HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF  
The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies...
US20180280499 PYRIMIDINE COMPOUND  
The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof,...
US20180280490 METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION  
Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can...
US20180280473 FORMULATION FOR TARGETING CANCER IN HUMANS AND CANINES USING CHLOROTOXIN  
The present invention provides formulation/composition comprising phytonutrients with natural chlorotoxins for targeting cancer, infection, inflammation and pain without any side effects and a...
US20180280301 IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES  
In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the...
10086060 Immunogenic proteins and compositions  
The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).
10086054 RM2 antigens and use thereof  
Described herein are synthetic glycan conjugates, immunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan...
US20180273912 INFLUENZA VIRUS AND TYPE 1 DIABETES  
Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The...
10076491 Vaccine composition  
The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.
US20180256701 PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS  
An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunisation. These polypeptides may...
US20180256695 COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT  
Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have...
US20180256694 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC)  
The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of...
10065994 Norovirus derived immunogenic compositions and methods  
The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a...
10064932 Integration of meningococcal conjugate vaccination  
The invention provides a method for immunizing a patient, comprising administering multiple conjugates meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or...
US20180243395 INJECTABLE VACCINES AGAINST MULTIPLE MENINGOCOCCAL SEROGROUPS  
An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated...
US20180243347 IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF  
The present disclosure provides immunomodulatory compositions comprising live Caulobacter crescentus (CC). Immunomodulatory compositions of the present disclosure are useful for modulating an...
10058608 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections  
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably...
10058607 Polyvalent pneumococcal polysaccharide-protein conjugate composition  
Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotype...
10058600 Detoxified Escherichia coli immunogens  
Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein....
US20180237786 ARTIFICIAL NUCLEIC ACID MOLECULES  
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR element) and/or at least one...
US20180237476 PRE-FUSION RSV F ANTIGENS  
The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion...
US20180236058 REVERSE GENETICS SYSTEMS  
The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.
US20180230187 INFLUENZA VACCINES  
Provided herein are compositions related to vaccines, e.g., influenza vaccines, including, peptide based vaccines, nucleic acid based vaccines, recombinant virus based vaccines, antibody based...
US20180228891 COMPOSITIONS OF VACCINES AND ADJUVANTS AND METHODS FOR THE TREATMENT OF URINARY TRACT INFECTIONS  
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably...
10047375 Artificial nucleic acid molecules  
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid...
10046048 Homogenous suspension of immunopotentiating compounds and uses thereof  
The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in...
10039816 Siderophore-based immunization against gram-negative bacteria  
The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention...
10035826 Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli  
Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing...
10034949 Polyvalent pneumococcal polysaccharide-protein conjugate composition  
Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotype...
10034835 Crosslinked vaccination composition  
The present invention is directed to vaccination composition comprising a particle comprising a polymer matrix incorporating an adjuvant and/or an antigen, to method of making them and use....
US20180207295 RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES  
The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the...
US20180207267 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF  
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.
US20180207258 ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE  
An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric...
10030231 Influenza virus reassortment  
Improved methods for the production of reassortant influenza viruses are provided.
10030052 Parvovirus Vp1 unique region polypeptides and compositions thereof  
The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for...
10022435 Nucleic acid vaccines  
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more...
US20180196061 INFLUENZA POTENCY ASSAYS  
The present application discloses stability-indicating potency assays for influenza vaccines.

« search again